The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PCVX | -52.86% | +19.87% | +3.69% | +74% |
| S&P | +12.57% | +87.93% | +13.44% | +122% |
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$5.20M | -15.4% |
| Market Cap | $4.68B | -66.4% |
| Market Cap / Employee | $11.30M | 0.0% |
| Employees | 414 | 63.0% |
| Net Income | -$212.83M | -106.4% |
| EBITDA | -$237.18M | -75.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $281.08M | -73.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $78.67M | 329.4% |
| Short Term Debt | $5.77M | -40.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -19.53% | 0.6% |
| Return On Invested Capital | -25.69% | 15.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$155.35M | -57.3% |
| Operating Free Cash Flow | -$143.31M | -136.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.98 | 1.43 | 1.31 | 1.52 | -76.07% |
| Price to Tangible Book Value | 2.98 | 1.43 | 1.31 | 1.52 | -76.07% |
| Enterprise Value to EBITDA | -54.31 | -20.12 | -12.87 | -13.82 | -84.38% |
| Return on Equity | -20.4% | -19.7% | -21.7% | -20.8% | -1.11% |
| Total Debt | $71.11M | $87.21M | $85.85M | $84.44M | 202.02% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
